NRX Pharmaceuticals, Inc. NRXP 深 沪
已收盘 05-15 16:00:00 美东时间
3.28
+0.070
+2.18%
华盛通- 最 高3.50
- 今 开3.25
- 成交量 225.04万股
- 最 低 3.2301
- 昨 收 3.21
- 总市值 10.85万
- 52周最高 3.84
- 市盈率 静 --
- 换手率 6805.55%
- 52周最低 1.62
- 委 比 -47.92%
- 总股本 3.31万
- 历史最高 769.90
- 量 比 2.11
- 振 幅 8.41%
- 历史最低 1.58
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year. The company reported $1.068 million in
05-16 05:55
NRx Starts Production Of Preservative-Free Ketamine Ahead Of FDA Decision, Expands Manufacturing, Builds Team For Expected Drug Launch
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces initiation of a first commercial manufacturing
05-05 19:13
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
04-27 19:07
美股牛股 | 特朗普签署行政令加速PTSD疗法研发！迷幻药物板块集体飙升，CMPS涨42%；军用无人机制造商Aevex上市两日股价涨近70%
特朗普签署行政令加速PTSD疗法研发！迷幻药物板块集体飙升，CMPS涨42%；国防科技IPO热度持续升温！军用无人机制造商Aevex上市两日股价涨近70%>>
04-21 15:31
NRx Pharmaceuticals Welcomes The Newly-Signed Presidential Executive Order: Accelerating Medical Treatments For Serious Mental Illness
In the Order, the President notes that, "It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and
04-20 19:02
NRx Pharmaceuticals Receives FDA Letter Regarding Comments On Minor Formatting Changes To Proposed Label For Its Preservative-Free Ketamine Product, The Company Expects To Submit Final Label In April
NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory review.NRx
04-06 19:05
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
03-25 00:27
NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 percent increase over losses of $(0.77) per share from the same period last year. The company reported $983.000 thousand
03-24 06:08
